Y-mAbs Therapeutics Inc. (YMAB)
Y-mAbs Therapeutics Statistics
Share Statistics
Y-mAbs Therapeutics has 45.22M shares outstanding. The number of shares has increased by 3.04% in one year.
| Shares Outstanding | 45.22M |
| Shares Change (YoY) | 3.04% |
| Shares Change (QoQ) | 0.96% |
| Owned by Institutions (%) | 64.43% |
| Shares Floating | 34.45M |
| Failed to Deliver (FTD) Shares | 3.62K |
| FTD / Avg. Volume | 0.9% |
Short Selling Information
The latest short interest is 3.66M, so 8.17% of the outstanding shares have been sold short.
| Short Interest | 3.66M |
| Short % of Shares Out | 8.17% |
| Short % of Float | 9.8% |
| Short Ratio (days to cover) | 11.23 |
Valuation Ratios
The PE ratio is -11.7 and the forward PE ratio is -4.48. Y-mAbs Therapeutics's PEG ratio is -0.32.
| PE Ratio | -11.7 |
| Forward PE | -4.48 |
| PS Ratio | 3.96 |
| Forward PS | 1.5 |
| PB Ratio | 3.77 |
| P/FCF Ratio | -22.09 |
| PEG Ratio | -0.32 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Y-mAbs Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.16, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.16 |
| Quick Ratio | 3.85 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.05 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $843.13K |
| Profits Per Employee | $-285.25K |
| Employee Count | 104 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 2.11 |
Taxes
| Income Tax | -146K |
| Effective Tax Rate | 0.49% |
Stock Price Statistics
The stock price has increased by -73.12% in the last 52 weeks. The beta is 0.7, so Y-mAbs Therapeutics's price volatility has been higher than the market average.
| Beta | 0.7 |
| 52-Week Price Change | -73.12% |
| 50-Day Moving Average | 5.05 |
| 200-Day Moving Average | 9.83 |
| Relative Strength Index (RSI) | 40.56 |
| Average Volume (20 Days) | 400.63K |
Income Statement
In the last 12 months, Y-mAbs Therapeutics had revenue of 87.69M and earned -29.67M in profits. Earnings per share was -0.67.
| Revenue | 87.69M |
| Gross Profit | 72.43M |
| Operating Income | -31.2M |
| Net Income | -29.67M |
| EBITDA | -31.2M |
| EBIT | -31.2M |
| Earnings Per Share (EPS) | -0.67 |
Balance Sheet
The company has 67.23M in cash and 820K in debt, giving a net cash position of 66.41M.
| Cash & Cash Equivalents | 67.23M |
| Total Debt | 820K |
| Net Cash | 66.41M |
| Retained Earnings | -487.14M |
| Total Assets | 119.9M |
| Working Capital | 74.81M |
Cash Flow
In the last 12 months, operating cash flow was -15.71M and capital expenditures 0, giving a free cash flow of -15.71M.
| Operating Cash Flow | -15.71M |
| Capital Expenditures | 0 |
| Free Cash Flow | -15.71M |
| FCF Per Share | -0.35 |
Margins
Gross margin is 82.61%, with operating and profit margins of -35.58% and -33.83%.
| Gross Margin | 82.61% |
| Operating Margin | -35.58% |
| Pretax Margin | -34% |
| Profit Margin | -33.83% |
| EBITDA Margin | -35.58% |
| EBIT Margin | -35.58% |
| FCF Margin | -17.92% |
Dividends & Yields
YMAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for YMAB is $20, which is 386.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $20 |
| Price Target Difference | 386.6% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
Scores
| Altman Z-Score | -1.23 |
| Piotroski F-Score | 2 |